Rejuvenate Biomed
Please select the button and submit the requested information to connect with the sponsor.
Rejuvenate Biomed is an independent Belgian biomedical company founded in 2017 by Dr. Ann Beliën, after nearly two decades of experience at Janssen Pharmaceutical companies of Johnson and Johnson.
The Rejuvenate Biomed team brings together over 100 years of relevant experience, covering all aspects of drug development.
Rejuvenate translates the science of keeping cells vital and resilient into human therapeutics to increase the healthy years of life. Based on their multi-applicable systems biology platform, the company identified multiple compounds.
For lead candidate RJx-01, a proprietary combination drug, the company generated preclinical evidence and safety in humans. The first clinical study will be run in sarcopenia (muscle failure), while opportunities in other age-related indications are identified for RJx-01.
The company is currently in Series B fundraising for 9 M€ with a lead life science venture capital investor on board.
Please select the button and submit the requested information to connect with the sponsor.